This protocol applies to women aged 18 or older with genital lichen sclerosus who are not pregnant and who have completed a first-line topical corticosteroid course without reaching the expected treatment goals.

First-Line Failure — Escalation Trigger

A completed course of ultrapotent or potent topical corticosteroids (clobetasol propionate or mometasone furoate) did not achieve the expected targets: complete remission of symptoms, healing of fissures and erosions, near-complete resolution of hyperkeratosis, or adequate softening of sclerosis. This protocol defines the next step.

Next-Step Approach (partial overview)

When topical corticosteroids are insufficient, the protocol calls for a topical calcineurin inhibitor as a second-choice or adjunctive option; for hyperkeratotic lesions that remain resistant to topical steroids — and in which malignancy has been excluded — an intralesional corticosteroid approach may also be considered. Full agent selection, sequencing, and duration are set out in the structured protocol.

Treatment goal: Suppression of symptoms — including pruritus, burning, and dyspareunia — assessed at 12 weeks.

References

DOI: 10.1111/jdv.20083

We recommend ultrapotent or potent topical corticosteroids in women with genital lichen sclerosus.
We suggest topical calcineurin inhibitors in women with genital lichen sclerosus as second choice or as an additional treatment if topical corticosteroids are contraindicated or insufficient. (off label)
We suggest intralesional corticosteroids to hyperkeratotic lesions in women with topical steroid-resistant genital lichen sclerosus (provided malignancy has been excluded).
In conclusion, TCIs twice daily for at least 12 weeks have some effect in suppressing symptoms (pruritus, burning, dyspareunia) in LS; however, clinical signs are usually better treated by potent topical steroids.

View source ↗

Genital Lichen Sclerosus in Women — Next Step When Topical Corticosteroids Have Not Achieved Remission

References